The pan-European STOXX Europe 600 index rose slightly, reflecting cautiously optimistic market sentiment as the European Central Bank’s recent interest rate cuts raised expectations for further monetary easing. In this environment, identifying high-growth tech stocks in Sweden requires looking for companies that can leverage innovation and adaptability to grow in an evolving economic landscape.
name
increase in revenue
revenue growth
growth assessment
true caller
20.45%
21.76%
★★★★★
EXBREN BIOPHARMA
53.90%
118.02%
★★★★★
hemnet group
20.11%
25.40%
★★★★★
scandion oncology
40.71%
75.34%
★★★★★
bio arctic
42.38%
98.40%
★★★★★
Biovica International
81.67%
78.55%
★★★★★
Ubico
20.52%
42.18%
★★★★★
bone support holding
33.76%
31.20%
★★★★★
Kebni
34.75%
86.11%
★★★★★
Scoron
32.63%
122.14%
★★★★★
Click here to see the complete list of 82 Swedish high-growth technology stocks and AI stock screeners.
Let’s find some gems from our expert screeners.
Simply Wall Street Growth Rating: ★★★★☆
Overview: BioGaia AB (Publisher) is a healthcare company that provides probiotic products worldwide and has a market capitalization of SEK 9.91 billion.
Operations: The Company focuses on the worldwide distribution of probiotic products and derives its revenue primarily from these products.
Despite a challenging year with revenue down 23%, BioGaia’s R&D spending and strategic focus on innovation remain strong, supporting a potential recovery. Annual revenue growth is expected to be 14.7%, higher than the Swedish market average of 0.9%, and profits are expected to grow by 21.2% annually, giving the company a strong position relative to market norms. The latest financial results revealed a weaker third-quarter net profit, which fell year-on-year from SEK 101.5 million to SEK 36.6 million. However, BioGaia’s consistent investment in research (no specific numbers provided) could drive significant advances in biotechnology and reinvigorate market stance and investor confidence.
OM:BIOG B Breakdown of revenue and expenses as of October 2024
Simply Wall Street Growth Rating: ★★★★★☆
Overview: Lime Technologies AB (publ) provides SaaS-based CRM solutions primarily in the Nordic region and has a market capitalization of SEK 4.53 billion.
Operations: The company generates revenue through the sale and implementation of CRM software systems, with a total amount of SEK 631.84 million.
Lime Technologies has navigated Sweden’s competitive technology environment and demonstrated strong financial health with an expected annual profit growth rate of 22.4% and an impressive annual expected revenue growth rate of 14.2%, making it one of the leading companies in the overall Swedish market. This is higher than the average of 0.9%. In particular, the company’s commitment to innovation is evident in its R&D spending trends that are strategically aligned with its growth trajectory, ensuring the sustainability of its software solution development. Despite facing challenges such as high debt levels, Lime’s recent financial results show that it plans to leverage its strong market position and increase shareholder value through focused investments and potential market expansion. Strategic initiatives aimed at achieving this goal were emphasized.
story continues
OM:LIME revenue and expense breakdown (as of October 2024)
Simply Wall Street Growth Rating: ★★★★☆
Overview: NCAB Group AB (publ) is a company that manufactures and sells printed circuit boards (PCBs) in Sweden, the Nordic region, Europe, North America and Asia, with a market capitalization of approximately SEK 12.23 billion.
Business Operations: The company primarily derives its revenue from operations in Europe, the Nordic region, North America, and East Asia. Europe was the largest contributor with SEK 2.02 billion, followed by the Nordic region and North America with SEK 777 million and SEK 767 million respectively.
NCAB Group, a leader in the Swedish technology sector, has shown resilience despite a difficult economic background. NCAB expects revenue growth of 9.3% per year, above the Swedish market average of 0.9%, and is in line with the market as evidenced by recent guidance predicting a year-over-year decline in third-quarter sales. is adapting to the downturn. The company’s commitment to innovation is underlined by R&D spending, which is critical to remaining competitive as demand in key European markets slows. Despite these hurdles, NCAB’s revenue is expected to grow 16.6% annually, suggesting solid internal efficiency and a strategic focus to stabilize its financial trajectory during uncertain times.
OM:NCAB’s revenue and expense breakdown as of October 2024
This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
Companies covered in this article include OM:BIOG B OM:LIME and OM:NCAB.
Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email us at editorial-team@simplywallst.com.
